Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotech giant Gilead Sciences (GILD 2.13%) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Gilead, and see what CAPS investors are saying about the stock right now.

Gilead facts

 

 

Headquarters (founded)

Foster City, Calif. (1987)

Market Cap

$85.1 billion

Industry

Biotechnology

Trailing-12-Month Revenue

$10.0 billion

Management

Chairman/CEO John Martin

President/COO John Milligan

Return on Equity (average, past 3 years)

36.5%

Cash/Debt

$1.9 billion / $8.0 billion

Competitors

Bristol-Myers Squibb 

GlaxoSmithKline

Pfizer 

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 97% of the 2,253 members who have rated Gilead believe the stock will outperform the S&P 500 going forward.

Just yesterday, one of those Fools, TMFTailwind, succinctly summed up the Gilead bull case for our community:

Very profitable company, and I expect [Gilead's] streak of profitability to continue to increase. No significant patent expiration until 2018. With the current success in the HIV market, if the company can find success in a new category via R&D efforts, this could turn out to be a big winner.